275 related articles for article (PubMed ID: 28576630)
21. Sirolimus Suppresses Phosphorylation of Cofilin and Reduces Interstitial Septal Thickness in Sporadic Lymphangioleiomyomatosis.
Huang YL; Chen PR; Lai YJ; Hsu HH
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445268
[TBL] [Abstract][Full Text] [Related]
22. Everolimus treatment of abdominal lymphangioleiomyoma in five women with sporadic lymphangioleiomyomatosis.
Mohammadieh AM; Bowler SD; Silverstone EJ; Glanville AR; Yates DH
Med J Aust; 2013 Jul; 199(2):121-3. PubMed ID: 23879512
[TBL] [Abstract][Full Text] [Related]
23. Chyloperitoneum, chylothorax and lower extremity lymphedema in woman with sporadic lymphangioleiomyomatosis successfully treated with sirolimus: a case report.
Chachaj A; Drozdz K; Chabowski M; Dziegiel P; Grzegorek I; Wojnar A; Jazwiec P; Szuba A
Lymphology; 2012 Jun; 45(2):53-7. PubMed ID: 23057149
[TBL] [Abstract][Full Text] [Related]
24. Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis: Results of a Phase I Clinical Trial.
El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Peters E; Haughey M; Bienfang D; Jones AM; Julien-Williams P; Cui Y; Villalba JA; Bagwe S; Maurer R; Rosas IO; Moss J; Henske EP
Chest; 2017 Jun; 151(6):1302-1310. PubMed ID: 28192114
[TBL] [Abstract][Full Text] [Related]
25. Pulmonary manifestations in tuberous sclerosis complex.
Gupta N; Henske EP
Am J Med Genet C Semin Med Genet; 2018 Sep; 178(3):326-337. PubMed ID: 30055039
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic Effect of Sirolimus for Lymphangioleiomyomatosis Remaining in the Abdominopelvic Region After Lung Transplantation: A Case Report.
Ito T; Suno M; Sakamoto K; Yoshizaki Y; Yamamoto K; Nakanishi R; Hirano Y; Irie M; Kurosaki T; Otani S; Yamane M; Sugimoto S; Miyoshi K; Oto T
Transplant Proc; 2016; 48(1):271-4. PubMed ID: 26915883
[TBL] [Abstract][Full Text] [Related]
27. Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges.
Goncharova EA; Krymskaya VP
J Cell Biochem; 2008 Feb; 103(2):369-82. PubMed ID: 17541983
[TBL] [Abstract][Full Text] [Related]
28. Sirolimus amelioration of clinical symptoms of recurrent lymphangioleiomyomatosis after living-donor lobar lung transplantation.
Sugimoto R; Nakao A; Yamane M; Toyooka S; Okazaki M; Aoe M; Seyama K; Date H; Oto T; Sano Y
J Heart Lung Transplant; 2008 Aug; 27(8):921-4. PubMed ID: 18656809
[TBL] [Abstract][Full Text] [Related]
29. Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis.
Lamattina AM; Taveira-Dasilva A; Goldberg HJ; Bagwe S; Cui Y; Rosas IO; Moss J; Henske EP; El-Chemaly S
Chest; 2018 Nov; 154(5):1070-1082. PubMed ID: 30144422
[TBL] [Abstract][Full Text] [Related]
30. Concentration of Serum Vascular Endothelial Growth Factor (VEGF-D) and Its Correlation with Functional and Clinical Parameters in Patients with Lymphangioleiomyomatosis from a Brazilian Reference Center.
Amaral AF; de Oliveira MR; Dias OM; Arimura FE; Freitas CSG; Acencio MMP; de Alvarenga VA; Kairalla RA; Carvalho CRR; Baldi BG;
Lung; 2019 Apr; 197(2):139-146. PubMed ID: 30623243
[TBL] [Abstract][Full Text] [Related]
31. Summaries for patients. Sirolimus therapy in patients with lymphangioleiomyomatosis.
Ann Intern Med; 2011 Jun; 154(12):I44. PubMed ID: 21690578
[No Abstract] [Full Text] [Related]
32. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
[TBL] [Abstract][Full Text] [Related]
33. COPD assessment test as a possible tool for evaluating health-related quality of life in lymphangioleiomyomatosis.
Kato M; Kanehiro Y; Yoshimi K; Kodama Y; Sekiya M; Sato T; Takahashi K; Seyama K;
Respir Investig; 2018 Nov; 56(6):480-488. PubMed ID: 30143460
[TBL] [Abstract][Full Text] [Related]
34. Lymphangioleiomyomatosis: Current understanding and potential treatments.
Moir LM
Pharmacol Ther; 2016 Feb; 158():114-24. PubMed ID: 26713679
[TBL] [Abstract][Full Text] [Related]
35. [Current understanding and perspectives of lymphangioleiomyomatosis].
Seyama K; Ando K; Hoshika Y; Suzuki Y; Takekawa H
Nihon Rinsho; 2013 Jun; 71(6):1103-8. PubMed ID: 23855221
[TBL] [Abstract][Full Text] [Related]
36. Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?
El-Chemaly S; Goldberg HJ; Glanville AR
Expert Rev Respir Med; 2014 Dec; 8(6):657-60. PubMed ID: 25199529
[TBL] [Abstract][Full Text] [Related]
37. A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis.
Lu C; Lee HS; Pappas GP; Dilling DF; Burger CD; Shifren A; Veeraraghavan S; Chapman JT; Parambil J; Ruoss SJ; Young LR; Hammes SR; Kopras EJ; Roads T; Krischer JP; McCormack FX;
Ann Am Thorac Soc; 2017 Jun; 14(6):919-928. PubMed ID: 28570161
[TBL] [Abstract][Full Text] [Related]
38. Sirolimus Therapy for Patients With Lymphangioleiomyomatosis Leads to Loss of Chylous Ascites and Circulating LAM Cells.
Harari S; Elia D; Torre O; Bulgheroni E; Provasi E; Moss J
Chest; 2016 Aug; 150(2):e29-32. PubMed ID: 27502989
[TBL] [Abstract][Full Text] [Related]
39. Use of CT Imaging to Quantify Progression and Response to Treatment in Lymphangioleiomyomatosis.
Gopalakrishnan V; Yao J; Steagall WK; Avila NA; Taveira-DaSilva AM; Stylianou M; Chen MY; Moss J
Chest; 2019 May; 155(5):962-971. PubMed ID: 30660784
[TBL] [Abstract][Full Text] [Related]
40. Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis?
Neurohr C; Hoffmann AL; Huppmann P; Herrera VA; Ihle F; Leuschner S; von Wulffen W; Meis T; Baezner C; Leuchte H; Baumgartner R; Zimmermann G; Behr J
Respir Res; 2011 May; 12(1):66. PubMed ID: 21600034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]